Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.

ABSTRACT:

Importance

Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness.

Objective

To test whether tocilizumab decreases mortality in this population.

Design, setting, and participants

The data for this study were derived from a multicenter cohort study of 4485 adults with COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with COVID-19 were categorized according to whether they received or did not receive tocilizumab in the first 2 days of admission to the I

SUBMITTER: Gupta S 

PROVIDER: S-EPMC7577201 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature